Cipla offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health. Its manufacturing facilities are located in Goa, Bengaluru, Baddi, Indore, Kurkumbh, Patalganga and Sikkim.Cipla offers a portfolio of inhalation products, with over 30 molecules and combinations across a range of devices, to suit individual patient needs. It manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. The Revolizer is a dry powder inhaler. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: HIV/AIDS, malaria, multi drug-resistant tuberculosis and reproductive health.

Cipla Vet is the Company's animal health division. It offers veterinary products in the categories, including companion care, equine, livestock, poultry, swine and aqua products. The Company's product range covers therapeutic segments, such as anti-infectives, anti-inflammatories, anti-thyroids, immunosuppressants, parasiticides, nutraceuticals and feed additives. Cipla Vet develops and manufactures various dosage forms, such as Spot-on, Oral Paste, Oral Powder, Sterile Injection, Beta Lactam oral formulation, Immunosuppressant Soft Gel Capsule and External Spray. It supplies animal health products in various markets, including the Australia, Brazil, Europe, Hong Kong, Mexico, New Zealand, Korea, South Africa, Turkey and United States.